Acetaminophen–butalbital–caffeine

Fioricet capsules relieve the symptom complex of tension/muscle-contraction headache. Label evidence for multiple recurrent headaches is unavailable, and butalbital is habit-forming. This product is not a codeine combination or a migraine preventive. Selected capsule record lists ANDA040885; other tablet strengths/manufacturers require separate identity and dose verification.

AHS’s Choosing Wisely recommendation advises against opioid- or butalbital-containing medicines as first-line treatment for recurrent headache disorders. This is distinct from the approved tension-headache indication and supports assessment of recurrent symptoms, frequent use, and dependence rather than default refill escalation.

Label dose: 1 or 2 capsules orally every 4 hours as needed; maximum 6 capsules per day. Six of the selected 50/300/40 mg capsules deliver butalbital 300 mg, acetaminophen 1,800 mg, and caffeine 240 mg. Extended/repeated use is not recommended because of physical dependence. The pediatric section says below 12 safety/effectiveness is unestablished; no separate validated pediatric weight-based schedule is supplied.

Do not exceed 4,000 mg/day acetaminophen from all sources; identify APAP on other pain/cold labels and avoid concurrent acetaminophen products as directed. This ceiling is not a target or permission to exceed 6 capsules, and liver disease/alcohol risks require individualized assessment.50/325/40 mg tablets, codeine-containing Fioricet, and aspirin-butalbital products have different ingredient totals and are outside this capsule regimen.

Do not suddenly stop prolonged/high-dose use when physical dependence is suspected; the label describes cautious gradual withdrawal because convulsions/delirium can follow abrupt cessation. No universal taper is supplied. Use caution with severe renal/hepatic impairment and in frail/older patients, using individualized selection rather than an invented CrCl dose table.

Known hypersensitivity or intolerance to any ingredient and porphyria are contraindications. Acetaminophen allergy precludes prescribing. The label’s severe renal/hepatic caution is not silently converted into a new formal contraindication or a validated reduced-dose regimen.

The box identifies acetaminophen-associated acute liver failure, sometimes requiring transplant or causing death. Many reported injuries involve doses above 4,000 mg/day and more than one APAP product. The selected capsule’s 6-per-day maximum remains separate and lower; the box does not imply doses below 4,000 mg are harmless in every patient.

Drowsiness, dizziness/lightheadedness, sedation, dyspnea, nausea/vomiting, abdominal pain, and intoxicated feeling are frequently reported. Other component effects include skin/allergic reactions and caffeine stimulation/tremor. Excess exposure can combine respiratory depression/coma/hypotension from butalbital with delayed APAP liver injury and caffeine arrhythmia. Obtain immediate emergency/poison assessment, even if symptoms are absent; clinicians assess APAP levels and N-acetylcysteine need while supporting airway/circulation. Do not attempt home charcoal, antidotes, or a self-selected detox taper.

Alcohol, opioid analgesics, anesthetics, tranquilizers, sedative-hypnotics, and other CNS depressants add CNS depression and should be avoided/reviewed as labeled. MAO inhibitors may enhance butalbital’s CNS effects; the label gives no universal washout or adjusted combination dose, so obtain medication-specific review rather than invent a 14-day rule.

Avoid other acetaminophen / APAP products and reconcile all daily totals. Acetaminophen can cause false-positive urinary 5-HIAA results; tell the ordering clinician about use. The selected label is not a comprehensive modern interaction database; no unsupported CYP adjustment or universal warfarin algorithm is added.

The label retains pregnancy-categoryC language, with no combination animal reproduction studies or established human safety; use only if clearly needed. Neonatal withdrawal seizures were reported after maternal butalbital exposure. Components enter milk; the label advises deciding whether to discontinue nursing or the drug based on maternal need because serious infant reactions are possible. This is not a claim that plain APAP’s lactation profile applies to butalbital.

Safety/effectiveness below 12 is unestablished. Older adult trial numbers were insufficient; start cautiously within the prescribed range and consider reduced renal/hepatic/cardiac function, frailty, and other medicines. The label does not supply a pediatric mg/kg regimen or guarantee benefit for chronic childhood headaches.

Use cautiously with severe renal/hepatic disease and monitor serial organ-function tests as labeled. Butalbital and its metabolites are largely renally eliminated; acetaminophen is hepatically metabolized. No validated stage-specific dose adjustment is provided, and liver risk is heightened with disease/alcohol.

Butalbital is a barbiturate, acetaminophen is a nonopioid analgesic/antipyretic, and caffeine is a CNS stimulant. The label states that their separate roles in the symptom complex are incompletely understood; no claim of proven migraine-specific action or dependence-free synergy is supplied.

Butalbital is well absorbed, distributes widely, and has an approximately 35-hour plasma half-life;59–88% of the dose is renally eliminated as drug/metabolites. APAP is rapidly absorbed, mainly liver-conjugated then renally eliminated, with labeled half-life 1.25–3 hours that may increase with liver injury/overdose. Caffeine is rapidly absorbed, crosses into fetal tissues/milk, and has about 3-hour half-life. These component figures do not establish identical dosing safety in organ impairment.

Review diagnosis, headache frequency, days of use, functional benefit, sedation/respiratory effects, increasing doses, alcohol/other CNS depressants, and withdrawal risk. Reconcile all APAP products. In severe renal/hepatic disease follow serial function tests as labeled; no universal laboratory interval or guaranteed safe long-term capsule schedule is established.

Take only the prescribed amount/frequency, never more than 6 selected capsules/day, and do not add APAP products. Avoid alcohol and hazardous tasks while affected. Report escalating use or difficulty stopping; do not abruptly stop dependent use. Seek immediate care for excess ingestion even if well, severe rash/allergy, slowed breathing, or severe withdrawal symptoms. Discuss pregnancy/breastfeeding and all medicines.

Fioricet 50/300/40 mg light-blue opaque capsules have FIORICET on the cap and a three-head profile on the body;100-count NDC 52544-080-01. Current DEA April 2026 exempt-prescription table specifically lists Actavis Fioricet 52544-080. That federal product exemption does not remove abuse risk, prove every butalbital product is exempt, or determine all state requirements.

Covered oral capsule contains butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg.50/325/40 mg tablets or other manufacturers, Fioricet with codeine, and aspirin-containing Fiorinal need their own label/dose/control-status review; no equivalence is assumed.

Store at 20–25°C in a tight, light-resistant container. Keep medication secure and inaccessible to children or others; the label identifies habit-forming potential. No unsupported opened-bottle expiration is supplied.